Thomas Englese
Direktor/Vorstandsmitglied bei Therakos (UK) Ltd.
Aktive Positionen von Thomas Englese
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Therakos (UK) Ltd.
Therakos (UK) Ltd. Medical/Nursing ServicesHealth Services Founded in 2012, Therakos (UK) Ltd. is a subsidiary of Mallinckrodt Plc. The company is based in Staines-upon-Thames, UK. The British company develops immune cell therapies that are delivered through extracorporeal photopheresis. | Direktor/Vorstandsmitglied | 30.10.2015 | - |
Karriereverlauf von Thomas Englese
Ehemalige bekannte Positionen von Thomas Englese
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
MALLINCKRODT PLC | Corporate Officer/Principal | 01.04.2015 | 01.07.2019 |
IKARIA, INC. | Corporate Officer/Principal | 01.10.2008 | 01.03.2015 |
BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.2002 | 01.01.2008 |
ELUTIA INC. | Corporate Officer/Principal | 01.07.2019 | - |
Ausbildung von Thomas Englese
The Pennsylvania State University | Masters Business Admin |
Villanova University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Vereinigtes Königreich | 2 |
Irland | 2 |
Operativ
Corporate Officer/Principal | 4 |
Director/Board Member | 1 |
Masters Business Admin | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
ELUTIA INC. | Health Technology |
MALLINCKRODT PLC | Health Technology |
BAXTER INTERNATIONAL INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Therakos (UK) Ltd.
Therakos (UK) Ltd. Medical/Nursing ServicesHealth Services Founded in 2012, Therakos (UK) Ltd. is a subsidiary of Mallinckrodt Plc. The company is based in Staines-upon-Thames, UK. The British company develops immune cell therapies that are delivered through extracorporeal photopheresis. | Health Services |
Ikaria, Inc.
Ikaria, Inc. BiotechnologyHealth Technology Ikaria, Inc. operates as a biotherapeutics company focused on developing and commercializing innovative therapeutics and interventions designed to meet the medical needs of critically ill patients. It offers INOMAX for inhalation, which is used to treat newborns suffering from hypoxic respiratory failure, and is making a major impact on the critical care environment. The company was founded on August 18, 2006 and is headquartered in Clinton, NJ. | Health Technology |
- Börse
- Insiders
- Thomas Englese
- Erfahrung